LDS/Medical Tests/PT and aPTT

PT and aPTT

The Coagulation Panel, or clotting screen, is used to evaluate clotting in patients who are suspected of or are showing an increased risk of clotting or bleeding-related diseases (hyper- or hypocoagulation). These tests measure the amount of time it takes to form a fibrin clot in the blood using the “intrinsic” and “extrinsic” coagulation pathways. The activated Partial Thromboplastin Time (aPTT) and Prothrombin Time (PT) are most often used to screen for an increased clotting time (hypocoagulation). Factors VIII, IX, XI, and XII comprise the intrinsic coagulation cascade (aPTT) and factors II, V, VII, and X comprise the extrinsic coagulation cascade (PT). Without proper clot formation, excessive bleeding could occur and could be fatal without treatment. Prolonged time of clot formation has many causes such as factor deficiency, factor inhibitors, oral anticoagulant therapy, vitamin K deficiency, or disseminated intravascular coagulation (DIC). There are also genetic disorders such as hemophilia, von Willebrand disease, or specific coagulation factor deficiencies that will lead to a deficient clotting process and prolong the aPTT and/or PT. The most common use of the activated partial thromboplastin time (aPTT) is to monitor patients on heparin therapy and the most common use of the prothrombin time (PT) is to monitor Coumadin/Warfarin therapy.

  • Screening for blood coagulation disorders such as a coagulation factor inhibitor (e.g., lupus anticoagulant), coagulation factor deficiency (e.g., hereditary or liver disease), circulating coagulation factor inhibitor or microangiopathic hemolyitic anemias such as DIC and TTP.
  • Used to monitor therapeutic anticoagulation drugs such as oral warfarin or heparin

Increased clotting time:

  • Hereditary clotting factor activity deficiency such as hemophilia A and B
  • Acquired coagulation factor deficiency
  • Coagulation factor inhibitor such as lupus anticoagulant/anti-phospholipid antibodies
  • Liver disease (decreased production) and DIC (increased consumption)
  • Vitamin K deficiency or vitamin-K antagonist (e.g., warfarin)

Decreased clotting time:

  • Hereditary clotting factor mutations such as Factor V Leiden or Factor II Prothrombin mutation that directly or indirectly interact with factors
  • Patients with mutation in co-factors such as protein S, protein C
  • Increased Factor VIII level

Prothrombin Time

In general: 11-15 sec

Newborn: Prolonged, reaches adult levels by 6 mo

Monitoring warfarin: INR* generally 2.0-3.0

Panic INR*: >6.0

INR*= International Normalized Ratio

 

Activated Partial Thromboplastin Time (aPTT) 

30 - 45 seconds
Panic:greater than or equal to 60 seconds

 

 

Prothrombin Time (PT) is measured by mixing a reagent, normally termed thromboplastin, with the patient’s plasma and measuring the time in seconds it takes for a clot to develop. Measurements are taken by optical or mechanical means.

Activated Partial Thromboplastin Time (aPTT) is measured via adding aPTT reagent and calcium to the patient’s plasma and measuring the time it takes in seconds for a clot to develop. Measurements are taken by optical or mechanical means.

Plasma Citrate (Light Blue). 

Freeze immediately and maintain frozen until tested.

Stability

  • Ambient: Unacceptable
  • Refrigerated: Unacceptable
  • Frozen: 14 days
Lupus anticoagulant, Antiphospholipid Antibody, Thrombin Time, Specific Factor Assays as indicated, Mixing Studies, Prekallikrein, von Willebrand Factor Assay, Factor V Leiden, Factor II (Prothrombin) Mutation.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Semin Oncol Nurs. 2005 Nov;21(4 Suppl 1):1-11. [PMID: 16360894]
  • Hamostaseologie. 2006 Jan;26(1):38-41. [PMID: 16444320]
  • Haemophilia. 2008 Jul;14 Suppl 3:104-12. [PMID: 18510529]
  • Lab Hematol. 2005;11:118. [PMID: 16024335]
  • Semin Thromb Hemost. 2005;31:17. [PMID: 15706471]
  • Hamostaseologie 2006;26:38. [PMID: 16444320]
  • Pathology Service, retrieved Jan 30, 2010 from: http://www2.massgeneral.org/pathology/coagbook/handbook.htm